Fox Chase Cancer Center News

PHILADELPHIA (November 21, 2018) — Research from Fox Chase Cancer Center shows that IL-23 and IL22 cytokines modulate microbiota composition and impact diet-induced atherosclerosis. 

PHILADELPHIA (November 27, 2018) – Christoph Seeger, PhD, has received a grant from the National Institutes of Health to identify the mechanism for cccDNA synthesis and identify cccDNA fate during cell division and nuclear localization using state of the art laboratory assays.

PHILADELPHIA (November 12, 2018) – The Press Ganey Guardian of Excellence Award recognizes outstanding clinical performance by our physicians and support staff in our outpatient clinics.

Stereotactic radiosurgery (SRS) offered results comparable to surgery in controlling local brain metastases, Fox Chase Cancer Center researchers have found. Early local control of treated lesions was better with SRS compared to those treated surgically, although the relative benefit decreased with time.

PHILADELPHIA (November 6, 2018) — Researchers at Fox Chase Cancer Center have created a mouse model that will make it possible to advance understanding of cystathionine beta synthase (CBS) deficiency, also known as classical homocystinuria.

PHILADELPHIA (November 5, 2018) — According to a new study, individuals living in rural areas are at greater risk of developing laryngeal cancer compared to those living in urban areas, though overall survival did not differ significantly between the two groups. Socioeconomic variables, including insurance status, had a greater impact on outcomes than geography or race.

PHILADELPHIA (November 1, 2018) — Stephen M. Sykes PhD, assistant professor in the Blood Cell Development and Function Program at Fox Chase Cancer Center, will conduct studies to assess the therapeutic utility of targeting downstream transcriptional targets and upstream activators within the unfolded protein response (UPR).

PHILADELPHIA (November 1, 2018) – The new Cancer Epigenetics Program Johnathan Whetstine, PhD, will lead has basic, translational, and clinical research components, all dedicated to better understanding epigenetic regulation in cancer.